Inclusion Criteria:

- 2nd or 3rd line of non squamous non small cell lung cancer of stage III or IV

- Document progression at the time of the inclusion. At least, one previous
chemotherapy line with platinum. Patient who had previous treatment with bevacizumab
can be included.

- Patient with active mutation of EGFR must have had on line of chemotherapy with
platinum and one with Tyrosine kinase inhibitor of EGFR.

- Patient with ALK rearrangement must have had at least one line of chemotherapy with
platinum and one with crizotinib.

Exclusion Criteria:

- Mixed cancer small cells and non small cells or squamous lung cancer.

- Central nervous system symptomatic metastasis or requiring immediate cerebral
radiotherapy

- patient who have had previous treatment with taxane (docetaxel, paclitaxel).
Peri-operatory chemotherapy with taxane allowed if stopped more than 6 months before.